|
 Xiping
Xu |
|
 |
|
| |
 Xiping
Xu M.D.
Professor of Epidemiology and Biostatistics
Adjunct Professor in Anhui Medical University
Ph D student advisor
RESEARCH INTERESTS:
Dr. Xiping Xu's special research interest focus on the common complex
diseases. His study areas include genetics epidemiology of asthma,
hypertension, osteoporosis and metabolic syndromes, and reproductive
health study; and pharmacogenomics of hypertension, diabetes and
hyperlipidemia. Significance in pharmacogenomics of complex diseases
is to observe individual difference on drug response and role of
gene polymorphisms that relevant to the pathways of drug metabolism
and biology of drug responses, as well as the pathological mechanisms
of these complex diseases. It helps to discover variation and determinants
of drug response and side effect, which may be applied in clinical
medicine for patient drug response prediction, and eventually may
help doctor to tailor treatment schema and choose more appropriate
drug dose to optimize the therapeutic goal for each patient. His
study feature in unifying the epidemiological principles of environmental,
occupational, nutritional and reproductive health fields with those
of population genetics, functional genomics and bioinformatics,
which provides a comprehensive approach to reveal the major environmental
factors and genetic bases that influence development of complex
diseases and individual differences of drug therapeutic responses.
Dr. Xiping Xu is excelling at evaluation and statistical analysis
of the interaction of environment and genetics, by applying the
state of art technology in study design, data collection and analysis,
research project management and quality control. His research team
has advanced laboratory equipment, well-trained technology personnel,
data management and analysis skills and study sites, which strongly
support the above studies ranking onto the world leading fields.
Dr. Xiping Xu has been devoted to develop and apply the theory
and findings in modern epidemiology, pharmacogenomics and biotechnology
for many years. These areas include (1) Environmental exposure(air,
water, occupational, nutritional) indicators;(2) Health outcome
(mortality, morbidity, functional and clinical phenotypes, intermediate
phenotype)indicators; (3) Biological and genetic biomarkers to reveal
heredity, vulnerability, multi-source exposures, and interactions
of gene and environment; (4) Developing community capacities for
research cohort and population-based longitudinal studies; (5)Building
up a dynamic multi-disciplinary knowledge and skill platforms for
supporting the clinical and field studies.
EDUCATION AND TRAINING:
He received Ph.D. from Tsukuba University in Japan in 1988. During
1985-1986, he worked in Department of Public Health and Hygiene
of Johns Hopkins University, USA. During 1988-1991, he worked in
Department of Environmental Epidemiology and Biostatistics, Harvard
School of Public Health (HSPH) as a visiting scholar. He obtained
his M.S .on Biostatics at HSPH in 1993. He has been the director
of Program of Population Genetics, HSPH since 1996. He has been
invited to be since 1998.
MAJOR GRANTS:
1. Pre-clinical study of new compound anti-hypertension drug, awarded
by the "10th five-year Science and Technology Breakthrough
Program", sponsored by the Anhui Provincial Science and Technology
Department;
2. Pharmacogenomics on the Common Chronic Diseases, awarded by the
Natural Sciences Fund Program, sponsored by the Anhui Provincial
Education Department;
3. Genetic Epidemiology of Osteoporosis, awarded by NIH;
4. Organophosphate Pesticides and Human Reproductive Health, awarded
by NIH;
5. Positional Candidate Gene Approaches in Asthma Gene Discovery,
awarded by NIH;
6. Cross-disciplinary Project of Reproductive Toxicology and Epidemiology,
awarded by NIH;
HONORS:
Professor Xu Xiping was rewarded as the scholar of "National
Cross-century 1 Billion Talented Scholar Project" (1st &
2nd Level) " in 1999, and as the scholar of "Hundred Excellence
Scholar Plan" by Chinese Academy of Sciences in 2000. He has
been awarded more than 10 NIH granted research projects as a Principle
Investigator. He published over 150 scientific articles in the peer-reviewed
and SCI-recoded journals. The impact factors of his publications
reached over 350.
|
| |
|
 |
|
 |
